Change over period: —
NSE · DRREDDY
DR.REDDY'S
0.0% from the 52-week high · +23.1% above the low
Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. The company is headquartered in Hyderabad, Telangana and currently employs 24,832 full-time employees. The Company’s segments include Global Generics, which is engaged in manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics); Pharmaceutical Services and Active Ingredients (PSAI), which is engaged in manufacturing and marketing active pharmaceutical ingredients and intermediates for finished pharmaceutical products; Proprietary Products, which focuses on research and development of differentiated formulations and Others, which consists of the Company’s wholly-owned subsidiary, Aurigene Discovery Technologies Limited, which is a discovery stage biotechnology company developing novel and therapies in the fields of oncology and inflammation.
The short version. DR.REDDY'S reported revenue of ₹8,698 crore for Sep 2026, down 1.5% from a year earlier. Net profit was ₹925 crore (down 31.3% year on year). Return on equity was 11.1% in Mar 2026. Promoter holding was 26.63% in Sep 2026, down 0.01 points over 8 quarters.
1 · The price
How has the stock traded?
DR.REDDY'S trades 0.0% at its 52-week high and 23.1% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹8,698 cr.
Sep 2026 net profit of ₹925 cr.
4.7 pts lower than a year earlier.
Revenue compounded at 10.9% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 8698 | 8100 | 7546 | 8753 | 8828 | 8572 | 8528 | 8381 |
| Net profit | 925 | 444 | 221 | 1210 | 1347 | 1418 | 1593 | 1414 |
| Net margin % | 10.6 | 5.5 | 2.9 | 13.8 | 15.3 | 16.5 | 18.7 | 16.9 |
| EPS (₹) | 11.08 | 5.32 | 2.65 | 14.5 | 16.14 | 16.99 | 19.09 | 16.94 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 33700 | 32644 | 28011 | 24670 | 21545 | 19048 | 17517 | 15448 |
| Net profit | 4196 | 5655 | 5578 | 4507 | 2182 | 1952 | 2026 | 1950 |
| Net margin % | 12.5 | 17.3 | 19.9 | 18.3 | 10.1 | 10.2 | 11.6 | 12.6 |
| EPS (₹) | 50.27 | 67.77 | 66.87 | 54.13 | 26.23 | 23.47 | 24.38 | 23.48 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 11.1% in Mar 2026; debt to equity is 0.17.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 11.1 | 16.9 | 19.7 | 19.4 |
| Return on capital % | 13.9 | 21.8 | 25.1 | 25.9 |
| EBITDA margin % | 22.3 | 28.6 | 30.5 | 28.8 |
| Net margin % | 12.0 | 16.8 | 19.3 | 17.5 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 10.9% | 12.6% |
| Profit CAGR | -2.4% | 16.5% |
4 · The owners
Who holds it, and are they adding?
Down 0.01 pts over 8 quarters.
Down 8.69 pts over 8 quarters.
Up 8.98 pts over 8 quarters.
+61 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 26.64 | 26.64 | 26.64 | 26.64 | 26.64 | 26.63 | 26.64 | 26.63 | -0.01 |
| FII | 40.08 | 37.29 | 36.36 | 35.52 | 33.2 | 33.08 | 32.07 | 31.39 | -8.69 |
| DII | 22.9 | 25.62 | 26.74 | 27.98 | 30.44 | 30.72 | 31.74 | 31.88 | +8.98 |
| Public | 10.22 | 10.15 | 10.0 | 9.61 | 9.47 | 9.33 | 9.35 | 9.9 | -0.32 |
Mutual fund holdings · Oct 2026
301 schemes hold this stock
240 the month before.
- ICICI Prudential Healthcare Fund9.64% of NAV
- ICICI Prudential Nifty Pharma ETF8.15% of NAV
- Nippon India Nifty Pharma ETF8.15% of NAV
- ICICI Prudential Nifty Pharma Index Fund8.15% of NAV
- ICICI Prudential Nifty Healthcare ETF7.15% of NAV
- Axis NIFTY Healthcare ETF7.15% of NAV
- DSP Nifty Healthcare ETF7.15% of NAV
- DSP Nifty Healthcare Index Fund7.15% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for DR.REDDY'S are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about DR.REDDY'S
What is the DR.REDDY'S share price?
DR.REDDY'S (DRREDDY) last closed at ₹1,386.30, down 0.85% on the day. Its 52-week range is ₹1,135.60 to ₹1,398.20.
What is the market cap of DR.REDDY'S?
DR.REDDY'S has a market capitalisation of about ₹116,297 crore. Its price-to-earnings ratio is 41.3.
How are DR.REDDY'S's latest results?
DR.REDDY'S reported revenue of ₹8,698 crore for Sep 2026, down 1.5% from a year earlier. Net profit was ₹925 crore (down 31.3% year on year). Return on equity was 11.1% in Mar 2026. Promoter holding was 26.63% in Sep 2026, down 0.01 points over 8 quarters.
Who owns DR.REDDY'S?
As of Sep 2026, shareholding was: Promoter 26.63%, FII 31.39%, DII 31.88%, Public 9.9%.
How many mutual funds hold DR.REDDY'S?
301 mutual fund schemes held DR.REDDY'S in October 2026. That compares with 240 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 10 Jul 2026 · Final Dividend - Rs. 8
- 10 Jul 2025 · Final Dividend - Rs. 8
- 28 Oct 2024 · Stock Split From Rs.5/- to Rs.1/-
- 16 Jul 2024 · Final Dividend - Rs. 40
- 11 Jul 2023 · Final Dividend - Rs. 40
- 11 Jul 2022 · Final Dividend - Rs. 30
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.